Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth

Krystal Biotech stock is up since its Q2 2026 earnings update, as investors react to double digit Vyjuvek revenue growth and strong margins while watching how guidance and cash reserves support the biotech story.

Krystal Biotech stock has advanced about 12% in the month since its latest earnings release, as the biotech company (ISIN US5012681064) rode double digit revenue growth from its gene therapy Vyjuvek in the second quarter of 2026 and outperformed the broader S&P 500, according to an analysis published by Zacks on September 2, 2026. The report notes that Krystal Biotech shares have climbed roughly 12% over that period while the S&P 500 delivered a smaller gain.

Q2 2026 earnings beat and revenue acceleration

In its second quarter 2026 update, Krystal Biotech reported earnings per share of 1.79 USD, beating the consensus estimate of 1.70 USD and improving from 1.29 USD in the same quarter of 2025, as summarized by Zacks on September 2, 2026. The same analysis highlights that this earnings beat reflects strong operational leverage as Vyjuvek sales scale.

Revenue in Q2 2026 reached 119.2 million USD, up from 96 million USD in the prior year period, which corresponds to a year over year increase of about 24.14%, driven entirely by Vyjuvek product sales according to the Zacks breakdown dated September 2, 2026. That report indicates that all reported revenue came from the companys only marketed drug.

Margins, cash position and spending guidance

For investors, Krystal Biotechs profitability profile is a key part of the story. The Zacks article dated September 2, 2026 states that the company achieved a gross margin of 95% in the quarter ended June 30, 2026, a level that reflects the high value nature of Vyjuvek and provides room to fund pipeline investments. The same earnings summary also points out that research and development expenses were about 14.5 million USD in Q2 2026, while selling, general and administrative expenses reached 39.9 million USD, rising 13.6% year over year due to higher headcount and marketing costs.

Krystal Biotech ended the quarter with cash, cash equivalents and investments totaling 1.1 billion USD as of June 30, 2026 compared with about 1.0 billion USD as of March 31, 2026, providing a sizeable buffer to support its commercial and clinical plans according to the Zacks write up on September 2, 2026. In addition, the company reiterated its non GAAP combined research and development and selling, general and administrative expense guidance for full year 2026 at a range of 175 million USD to 195 million USD, signaling disciplined operating spending alongside revenue growth.

Vyjuvek as the commercial growth driver

Vyjuvek, Krystal Biotechs gene therapy for dystrophic epidermolysis bullosa, remains the sole commercial revenue source and is central to the investment case. According to the Zacks review of the companys Q2 2026 performance published on September 2, 2026, Vyjuvek generated the full 119.2 million USD in product revenue in the second quarter, up from 96 million USD one year earlier, which underlines robust patient uptake and expanding access in approved markets. The same analysis notes that the strong top line performance provides resources for Krystal Biotech to advance additional pipeline assets in genetic dermatology and related indications.

Stock performance and investor perspective

Zacks highlighted on September 2, 2026 that Krystal Biotech stock has risen around 12% since the release of its Q2 2026 results, while also assigning the shares an overall VGM Score of D and a Zacks Rank of 3, indicating an expected in line return relative to the broader market in the coming months. For growth oriented investors, the combination of a 24.14% year over year revenue increase in Q2 2026 and a 95% gross margin offers a clear quantitative picture of how the companys first commercial product is scaling.

For comparison within the medical, biomedical and genetics universe, the same Zacks report dated September 2, 2026 references that another large industry player, AstraZeneca, delivered 6.4% year over year revenue growth in its quarter ended June 2026 and carries a similar Zacks Rank of 3, underscoring that Krystal Biotechs current top line growth rate is higher even if its valuation and risk profile differ as a smaller biotech.

Stock price context and trading venue

Krystal Biotech shares trade on the Nasdaq in United States dollars under the ticker KRYS, giving European investors exposure primarily through the US listing rather than a DACH exchange. While many German investors in biotech look at large cap peers like CSL or European names listed in the DAX and MDAX, companies such as Krystal Biotech offer a more focused single product gene therapy profile that complements the broader sector.

As of early September 2026, market data compiled in North American stock portals indicate that Krystal Biotech stock has moved in line with its recent 12% post earnings gain referenced by Zacks, leaving the shares above their pre Q2 2026 earnings levels and reflecting investors willingness to pay for high margin gene therapy growth. For holders, the next milestones will be further quarterly updates on Vyjuvek patient numbers, any new regulatory decisions and the development of additional clinical candidates backed by the companys 1.1 billion USD cash position as of June 30, 2026.

Vyjuvek underscores Krystal Biotechs gene therapy focus

Vyjuvek is a topical gene therapy designed for patients with dystrophic epidermolysis bullosa, a rare and severe skin disorder, and it underpins Krystal Biotechs current commercial profile. The Q2 2026 figures summarized by Zacks on September 2, 2026 confirm that Vyjuvek alone delivered 119.2 million USD in quarterly product revenue, up 24.14% year over year, which gives investors a concrete view of how a single differentiated product can build a meaningful revenue base in a specialized indication. Given the 95% gross margin reported for the same quarter, each incremental Vyjuvek prescription offers a significant contribution to covering operating expenses and funding future pipeline programs.

Krystal Biotech stock and what investors watch next

For Krystal Biotech stock, the central question over the coming quarters will be whether the company can maintain its current momentum in Vyjuvek sales and convert its strong cash balance of 1.1 billion USD as of June 30, 2026 into a broader portfolio of approved therapies. With second quarter 2026 revenue growing from 96 million USD to 119.2 million USD and earnings per share rising from 1.29 USD to 1.79 USD compared with the prior year quarter, management has demonstrated that gene therapy can deliver both top line growth and profitability, which differentiates Krystal Biotech from many early stage peers that are still pre revenue.

At the same time, guidance for combined non GAAP research and development and selling, general and administrative expenses between 175 million USD and 195 million USD for full year 2026 indicates that the company intends to continue investing at a substantial level in both commercialization and development activities. Investors will therefore closely follow each quarterly update to see how Vyjuvek revenue growth balances against this spending corridor and how that balance translates into future earnings per share trends beyond the 1.79 USD achieved in Q2 2026.

Key data on Krystal Biotech

• Company: Krystal Biotech, Inc.
• ISIN: US5012681064
• Ticker: KRYS
• Trading venue: NASDAQ
• Sector / Industry: Health care / Biotechnology
• Index membership: Not part of major blue chip indices